{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:33:00Z","timestamp":1786120380886,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5,15]]},"DOI":"10.1097\/tp.0b013e31824ad60a","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T19:54:41Z","timestamp":1331063681000},"page":"887-894","source":"Crossref","is-referenced-by-count":30,"title":["Randomized Trial Comparing Late Concentration-Controlled Calcineurin Inhibitor or Mycophenolate Mofetil Withdrawal"],"prefix":"10.1097","volume":"93","author":[{"given":"Jacqueline S.","family":"Mourer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan den","family":"Hartigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik W.","family":"van Zwet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko J.K.","family":"Mallat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Dubbeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210129","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-6143.2006.01688.x","article-title":". Banff 05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN).","volume":"7","author":"Solez","year":"2007","journal-title":"Am J Transplant"},{"key":"R2-7-20210129","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/00007890-199812270-00029","article-title":"Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group.","volume":"66","author":"Solez","year":"1998","journal-title":"Transplantation"},{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":". The natural history of chronic allograft nephropathy.","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"R4-7-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","article-title":". Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology.","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1523-1755.2005.00085.x","article-title":". Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy.","volume":"67","author":"Ishii","year":"2005","journal-title":"Kidney Int"},{"key":"R6-7-20210129","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","article-title":". Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study.","volume":"7","author":"Ekberg","year":"2007","journal-title":"Am J Transplant"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":". Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-7-20210129","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1523-1755.2003.00175.x","article-title":". Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy.","volume":"64","author":"Bakker","year":"2003","journal-title":"Kidney Int"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.TP.0000144181.47045.FE","article-title":". A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results.","volume":"78","author":"Gallagher","year":"2004","journal-title":"Transplantation"},{"key":"R10-7-20210129","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/TP.0b013e318195a421","article-title":". Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis.","volume":"87","author":"Moore","year":"2009","journal-title":"Transplantation"},{"key":"R11-7-20210129","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-6143.2003.30112.x","article-title":". Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection.","volume":"3","author":"Meier-Kriesche","year":"2003","journal-title":"Am J Transplant"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/00007890-200212270-00015","article-title":". Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study.","volume":"74","author":"Abramowicz","year":"2002","journal-title":"Transplantation"},{"key":"R13-7-20210129","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2004100844","article-title":". Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study.","volume":"16","author":"Abramowicz","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":". Therapeutic drug monitoring of mycophenolate mofetil in transplantation.","volume":"28","author":"van Gelder","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R15-7-20210129","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":". A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1600-6143.2004.00404.x","article-title":"Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy.","volume":"4","author":"Suwelack","year":"2004","journal-title":"Am J Transplant"},{"key":"R17-7-20210129","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.TP.0000151632.21551.00","article-title":". Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: The creeping creatinine study.","volume":"79","author":"Dudley","year":"2005","journal-title":"Transplantation"},{"key":"R18-7-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":". Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"R19-7-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00007890-198707000-00027","article-title":". Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function.","volume":"44","author":"English","year":"1987","journal-title":"Transplantation"},{"key":"R20-7-20210129","first-page":"S70","article-title":"Cyclosporine-induced renal dysfunction in experimental animals and humans.","volume":"52","author":"Remuzzi","year":"1995","journal-title":"Kidney Int Suppl"},{"key":"R21-7-20210129","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/ki.1996.183","article-title":". Cyclosporine induces glomerulosclerosis: Three-dimensional definition of the lesions in a rat model of renal transplant.","volume":"49","author":"Perico","year":"1996","journal-title":"Kidney Int"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1097\/00007890-199912150-00019","article-title":". Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow.","volume":"68","author":"Vieira","year":"1999","journal-title":"Transplantation"},{"key":"R23-7-20210129","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1046\/j.1523-1755.2001.059002498.x","article-title":". Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.","volume":"59","author":"Islam","year":"2001","journal-title":"Kidney Int"},{"key":"R24-7-20210129","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1681\/ASN.2005080891","article-title":". Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies.","volume":"17","author":"Roos-van Groningen","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1681\/ASN.2005030249","article-title":". No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.","volume":"17","author":"Rowshani","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"F769","DOI":"10.1152\/ajprenal.00281.2005","article-title":"An emerging role for calcineurin Aalpha in the development and function of the kidney.","volume":"290","author":"Gooch","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"R27-7-20210129","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/01.tp.0000251423.78124.51","article-title":". Loss of the alpha-isoform of calcineurin is sufficient to induce nephrotoxicity and altered expression of transforming growth factor-beta.","volume":"83","author":"Gooch","year":"2007","journal-title":"Transplantation"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1681\/ASN.V132536","article-title":". Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen.","volume":"13","author":"Schnuelle","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R29-7-20210129","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/01.ASN.0000013298.11876.BF","article-title":". Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study.","volume":"13","author":"Smak Gregoor","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R30-7-20210129","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1681\/ASN.2005030312","article-title":". Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial.","volume":"16","author":"Hazzan","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R31-7-20210129","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":". Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The Opticept trial.","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transplant"},{"key":"R32-7-20210129","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/ndt\/gfg065","article-title":". A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients.","volume":"18","author":"Cremers","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R33-7-20210129","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/j.1523-1755.2005.00352.x","article-title":". AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients.","volume":"67","author":"Scholten","year":"2005","journal-title":"Kidney Int"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-201205150-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:41:21Z","timestamp":1786048881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201205150-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,15]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e31824ad60a","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5,15]]}}}